Clincosm LogoSign in Get a demo

Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

Sponsor
Assiut University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03283228
Collaborator
(none)
30
Enrollment
22
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

  1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.

  2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Cd11b and Cd56 markers

Detailed Description

  1. CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could predict a poor prognosis for AML patients.

  2. CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely related to the prognosis of AML patients

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Anticipated Study Start Date :
Dec 1, 2017
Anticipated Primary Completion Date :
Dec 1, 2018
Anticipated Study Completion Date :
Oct 1, 2019

Arms and Interventions

Arm Intervention/Treatment
CD11b and CD56 markers

Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

Diagnostic Test: Cd11b and Cd56 markers
The expression of CD11b and CD56 in newly diadnosed cases of AML
Other Names:
  • Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

    		•
    Haematological parameters in cases of adult AML

    Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML

    Diagnostic Test: Cd11b and Cd56 markers
    The expression of CD11b and CD56 in newly diadnosed cases of AML
    Other Names:
  • Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

    		•

    Outcome Measures

    Primary Outcome Measures

    1. CD11b and CD56 marker [24 month]

      Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 50 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Anew diagnosis cases of adult AML

    Exclusion Criteria:

    1. Pediatric AML .

    2. follow up cases of adult AML

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Z A Kamel, Dr, Assiut University
    ClinicalTrials.gov Identifier:
    NCT03283228
    Other Study ID Numbers:
    • Myeloid Leukemia Markers
    First Posted:
    Sep 14, 2017
    Last Update Posted:
    Sep 14, 2017
    Last Verified:
    Sep 1, 2017
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Leukemia
    Leukemia, Myeloid
    Leukemia, Myeloid, Acute

    Study Results

    No Results Posted as of Sep 14, 2017